Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study.

Michela Casanova Francisco J Bautista Sirvent Quentin Campbell-Hewson Guy Makin Lynley V Marshall Arnauld C Verschuur Adela Cañete Nieto Nadège Corradini Bart A Ploeger Barbara J Brennan Udo Mueller Hong Zebger-Gong John W Chung Didier Frappaz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (clinicaltrials.gov NCT02085148).

Keyphrases

metastatic colorectal cancer
papillary thyroid
acute lymphoblastic leukemia
young adults
acute myeloid leukemia
childhood cancer
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma
squamous cell
squamous cell carcinoma
lymph node metastasis